Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
Page 2

Furthermore, it is also noted that suitable bioequivalence methods are lacking for many generic ophthalmic formulations, including suspensions and emulsions. Therefore an investigation of the relationship between various physicochemical properties and their effect on ocular bioavailability will help the FDA in establishing guidelines for the determination of bioequivalence of ophthalmic suspensions and emulsions.

The scope of the program will cover two types of inquiries:

a) In vitro study – Formulations with different physicochemical properties are manufactured using a selected steroid and characterized in vitro. Drug release and stability tests are conducted to understand how differences in physicochemical properties may affect ocular bioavailability.

b) In vivo study – Formulations selected based on the results of the in vitro study are tested in an animal model. A pharmacokinetic study should be conducted by assessing the ocular distribution of the steroid in various eye tissues and organs at various time points.

In order to support these initiatives, the Food and Drug Administration is set to administer funds in the amount of $400,000.

The institutions and organizations who will be deemed eligible to submit an application under this program are the following:

a) Private and Public Non-profit entities

b) State and Local Governments

c) Indian Tribal Governments and Organizations

d) Faith-based Organizations

e) Community-based Organizations

f) Institutions of Higher Education

g) Private and Public Colleges and Universities

h) Independent School Districts

The United States Department of Health and Human Services, the mother agency funding the Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program, is country's premiere agency for protecting the health of all Americans and providing essential human services, especially to those who medically challenged and vulnerable.

Effect of Physicochemical Properties of Ophthalmic Formulations on Ocular Bioavailability Program
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Rural Health Research Center Program
The Health Resources and Services Administration has recently established the Rural Health Research Center (RHRC) Cooperative Agreement Program in an attempt to substantially improve the amount of high-quality, impartial, policy-relevant research studies.

---

Health Care Innovation Challenge
The Centers for Medicare and & Medicaid Services has recently established the Health Care Innovation Challenge in an attempt to solicit proposals to establish interesting new models of service delivery that can potentially deliver the three-part aim of better health, better health care, and finally, lower costs through the improved quality of Medicare, Medicaid, and Children's Health Insurance Program.

---

Clinical Trials for Organ Transplantation in Children Program
The National Insitutes of Health has formed a partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to establish the Clinical Trials for Organ Transplantation in Children Program wherein both agencies intend to support a group of investigators in their quest of conducting clinical trials regarding pediatric solid organ transplant recipients.

---

Lifespan Respite Care Program - Technical Assistance Resource Center
In keeping with this mission, the Administration on Aging has recently announced the constitution of the Lifespan Respite Care Program - Technical Assistance Resource Center wherein it aims to invite applications for a competitive grant opportunity for implementing the requirements of the Technical Assistance Resource Center (TARC) as authorized in the Lifespan Respite Care Act of 2006.

---